The second edition of Oncology Clinical Trials has been thoroughly revised and updated and now contains the latest designs and methods of conducting and analyzing cancer clinical trials in the era of precision medicine with biologic agents-including trials investigating the safety and efficacy of targeted therapies, immunotherapies, and combination therapies as well as novel radiation therapy modalities. Now divided into five sections this revamped book provides the necessary background and expert guidance from the principles governing oncology clinical trials to the innovative statistical design methods permeating the field; from conducting trials in a safe and effective manner, analyzing and interpreting the data, to a forward-looking assessment and discussion of regulatory issues impacting domestic, international, and global clinical trials. Considered by many as the gold standard reference on oncology clinical trials in the field, the second edition continues to provide examples of real-life flaws and real-world examples for how to successfully design, conduct and analyze quality clinical trials and interpret them. With chapters written by oncologists, researchers, biostatisticians, clinical research administrators, and industry and FDA representatives, this volume provides a comprehensive guide in the design, conduct, monitoring, analysis, and reporting of clinical trials in oncology. New to this Edition: Outlines how to design clinical trials with and without biomarker testing-including genomics-based "basket" trials, and adaptive trials for all phases during treatment and quality-of-life trials Includes new chapters on immunotherapy trials, radiation therapy trials, multi-arm trials, meta-analysis and adaptive design, use of genomics, dose modifications and use of ancillary treatments in investigational studies, establishing surrogate endpoints, practical issues with correlative studies, cost-effectiveness analysis, and more Comprehensively covers all regulatory aspects in the pursuit of global oncology trials Digital Access to the eBook included

Precision medicine is a rapidly-evolving field in the management of cancer. The use of novel molecular or genetic signatures in local-regional management is still in its infancy. Precision Radiation Oncology demystifies this state-of-the-art research and technology. By describing current existing clinical and pathologic features, and focusing on the ability to improve outcomes in cancer using radiation therapy, this book discusses incorporating novel genomic- or biology-based biomarkers in the treatment of patients moving radiation oncology into precision/personalized medicine. Precision Radiation Oncology provides readers with an overview of the new developments of precision medicine in radiation oncology, further advancing the integration of new research findings into individualized radiation therapy and its clinical applications.

Drug resistance in cancer, whereby a proportion of cancer cells evades chemotherapy, poses a profound and continuing challenge for the effective treatment of cancer. The principles underlying the biological mechanisms behind this phenomenon are clearly understood and explained in this volume. However, a deeper understanding of drug resistance requires a quantitative appreciation of the dynamic forces that shape tumour growth, including spontaneous mutation and selection processes. The authors seek to explain and to simplify these complex mechanisms, and to place them in a clinical context. Clearly explained mathematical models are used to illustrate the biological principles and provide an insight into tumour development and the effectiveness and limitations of drug treatment. It is suitable for those with a non-mathematical background and aims to enhance the effectiveness of cancer therapy.

The development of drug-resistant cancers is considered to be the most significant obstacle to the cure of cancer today. Nearly half of all patients with cancer suffer from tumours that are intrinsically resistant to chemotherapy, and most of the remaining half develop drug resistance during the course of their treatment. This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority. Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support. The authors are among the leading clinicians and investigators in the field. These authoritative volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

This second edition of the Oxford Handbook of Cancer Nursing is an essential aid to the practising cancer nurse. It provides a quick reference to the key issues in cancer nursing, and a concise and systematic account of all of the main areas of cancer nursing practice. Filled with key tips and reflection points, each chapter supports professional development for the reader. The patient, their family, and the experience of cancer are at the heart of this handbook. For the new edition there is a greater focus on survivorship, drawing on recent developments in the area. The Oxford Handbook of Cancer Nursing promotes a multidisciplinary approach to cancer care, with references to current best evidence and the latest developments in treatment. Detailed guidance on complex aspects of care are outlined, integrating both psychosocial and physical care to better treat the whole patient. Written by experienced nurses, the book is laid out to enable quick access to precise, targeted information on the vast majority of potential clinical scenarios.